Related Experiment Video

Updated: Jun 24, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

Anti-inflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats

K Mousavizadeh1, R Rahimian, G Fakhfouri

  • 1Iran University of Medical Sciences, Tehran. pedram.ghafourifar@TIPSwv.com

European Journal of Clinical Investigation
|March 24, 2009
PubMed
Abstract

Insights

Tropisetron, a 5-Hydroxytryptamine (5-HT)-3 receptor antagonist, demonstrated anti-inflammatory effects in a rat model of experimental colitis. This suggests potential therapeutic benefits for inflammatory bowel disease (IBD) treatment.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) requires novel therapeutic strategies.
  • Tropisetron, a 5-Hydroxytryptamine (5-HT)-3 receptor antagonist, possesses known anti-inflammatory properties.
  • Investigating tropisetron's efficacy in experimental colitis is crucial for IBD treatment development.

Purpose of the Study:

  • To evaluate the therapeutic potential of tropisetron in an acetic acid-induced rat colitis model.
  • To assess the impact of tropisetron on colonic damage, inflammation, and oxidative stress markers.
  • To compare the effects of tropisetron with dexamethasone, a standard anti-inflammatory drug.

Main Methods:

  • An acetic acid-induced colitis model was established in rats.
  • Tropisetron and dexamethasone were administered via intraperitoneal (IP) or intrarectal (IR) routes.
  • Colonic damage, neutrophil infiltration (myeloperoxidase activity), lipid peroxidation (malondialdehyde), and inflammatory cytokines (IL-1β, IL-6, TNF-α) were assessed.

Main Results:

  • Tropisetron significantly reduced macroscopic and microscopic colonic damage.
  • Treatment with tropisetron led to decreased neutrophil infiltration, lipid peroxidation, and inflammatory cytokine levels.
  • While effective, tropisetron's beneficial effects were less pronounced than those of dexamethasone.

Conclusions:

  • Tropisetron exhibits significant anti-inflammatory and protective effects in experimental rat colitis.
  • These findings support the potential utility of tropisetron as a therapeutic agent for inflammatory bowel disease (IBD).
  • Further research into tropisetron's mechanism and clinical application in IBD is warranted.

More Related Videos

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium04:05

A Rat Model of Pouchitis Following Proctocolectomy and Ileal Pouch-Anal Anastomosis Using Dextran Sulfate Sodium

Published on: May 31, 2024

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...